Cargando…
Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
Autores principales: | Zaccardi, Francesco, Kloecker, David E., Buse, John B., Mathieu, Chantal, Khunti, Kamlesh, Davies, Melanie J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441544/ https://www.ncbi.nlm.nih.gov/pubmed/33334809 http://dx.doi.org/10.2337/dc20-2080 |
Ejemplares similares
-
Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes
por: Zaccardi, Francesco, et al.
Publicado: (2022) -
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
por: Crowley, Matthew J., et al.
Publicado: (2020) -
Age at diagnosis of type 2 diabetes and cardiovascular risk factor profile: A pooled analysis
por: Barker, Mary M, et al.
Publicado: (2022) -
Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People With Diabetes in England During the COVID-19 Pandemic
por: Valabhji, Jonathan, et al.
Publicado: (2021) -
Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis
por: Vetrone, Lorenzo M., et al.
Publicado: (2018)